--- title: "111, Inc. Posts Lower Q1 2026 Revenue as Asset-Light Shift Boosts High-Margin Services" type: "News" locale: "en" url: "https://longbridge.com/en/news/288711030.md" description: "111, Inc. (YI) reported a 33.1% YoY drop in Q1 2026 net revenue to RMB2.4 billion due to divesting underperforming subsidiaries and shifting to an asset-light model. While gross segment profit fell 35.4%, marketplace service revenue grew 24.7% and promotional product revenue surged 70.2%. Fulfillment expenses decreased by 34.6%. TipRanks' AI Analyst rates YI as Neutral, citing stressed financials despite improved cash generation." datetime: "2026-06-04T11:17:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288711030.md) - [en](https://longbridge.com/en/news/288711030.md) - [zh-HK](https://longbridge.com/zh-HK/news/288711030.md) --- # 111, Inc. Posts Lower Q1 2026 Revenue as Asset-Light Shift Boosts High-Margin Services 111 ( (YI) ) just unveiled an announcement. On June 4, 2026, 111, Inc. reported unaudited results for the first quarter ended March 31, 2026, highlighting a 33.1% year-over-year drop in net revenue to RMB2.4 billion as it divested underperforming subsidiaries and shifted to an asset-light, warehouse-partnership model. Despite lower topline and a 35.4% decline in gross segment profit, marketplace service revenue grew 24.7%, promotional product revenue surged 70.2% with a 75.0% gross profit increase—driven by flagship drug Cravit—and fulfillment expenses fell 34.6% and improved as a share of revenue, underscoring progress in repositioning the business toward higher-margin platform services and greater operational efficiency for stakeholders. **Spark’s Take on YI Stock** According to Spark, TipRanks’ AI Analyst, YI is a Neutral. The score is held down primarily by a stressed financial profile—declining revenue, very thin gross margins, and a balance sheet with negative equity—despite a meaningful improvement in cash generation and reduced losses. Technically, momentum is weak with the price below key moving averages and a negative MACD, although oversold indicators offer only limited support. Valuation is hard to assess with a negative P/E and no dividend data. To see Spark’s full report on YI stock, click here. **More about 111** 111, Inc. is a Shanghai-based, tech-enabled healthcare platform listed on Nasdaq under the ticker YI. The company focuses on digitally empowering China’s pharmaceutical value chain, providing B2B and B2C medicine distribution, marketplace services, and digital marketing solutions to drugmakers, pharmacies, and healthcare providers across the country. **Average Trading Volume:** 15,718 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $47.79M See more data about YI stock on TipRanks’ Stock Analysis page. ### Related Stocks - [YI.US](https://longbridge.com/en/quote/YI.US.md) ## Related News & Research - [FREDUN: Strong revenue and profit growth with robust compliance in the pharmaceutical segment](https://longbridge.com/en/news/294919739.md) - [Actinium Pharmaceuticals, Inc. Q2 2026: Revenue $35M, EPS $0.89— 10-Q Summary](https://longbridge.com/en/news/295279109.md) - [Madrigal Pharmaceuticals grants 4,263 inducement RSUs to 10 new employees](https://longbridge.com/en/news/295143931.md) - [Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook](https://longbridge.com/en/news/294866410.md) - [Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement](https://longbridge.com/en/news/294867785.md)